Transcept Pharmaceuticals to Report First Quarter 2010 Results and Host Conference Call on May 12, 2010

News provided by

Apr 28, 2010, 04:05 ET

POINT RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it plans to release first quarter 2010 financial results on May 12, 2010, after the close of the market. At 5:00 p.m. Eastern Time, Transcept management will host a webcast and teleconference to discuss these results.

Conference Call Information
	Date: Wednesday, May 12, 2010
	Time: 5:00 p.m. EDT
	Dial-in (U.S.): 877-638-4558
	Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website beginning shortly after the conclusion of the call through June 11, 2010.

A telephone replay of the conference call will be available beginning shortly after the conclusion of the call through May 28, 2010. The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 68539754.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.